Nordic Nanovector Sees Significant Improvement in Patient Recruitment Rate in PARADIGME, its Single-arm Phase 2 Pivotal Trial with Betalutin® in R/R Follicular Lymphoma
Oslo, Norway, 18 February 2021 Nordic Nanovector ASA (OSE: NANOV) provides an update on PARADIGME, its ongoing pivotal Phase 2b trial of Betalutin® ([177]Lu lilotomab satetraxetan) in 3[rd]-line relapsed/refractory follicular lymphoma (3L R/R FL). Despite COVID has the company seen a significant improvement in the enrolment rate from approximately two to approximately five patients per month. After the expected lessening of COVID restrictions plus the ongoing operational improvements, this rate could further increase to at least seven patients on average per month by late spring.